CA2926267C - Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors - Google Patents

Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors Download PDF

Info

Publication number
CA2926267C
CA2926267C CA2926267A CA2926267A CA2926267C CA 2926267 C CA2926267 C CA 2926267C CA 2926267 A CA2926267 A CA 2926267A CA 2926267 A CA2926267 A CA 2926267A CA 2926267 C CA2926267 C CA 2926267C
Authority
CA
Canada
Prior art keywords
cells
cell
lymphocytes
antibody
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2926267A
Other languages
English (en)
French (fr)
Other versions
CA2926267A1 (en
Inventor
Dario Campana
Ko KUDO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University of Singapore
St Jude Childrens Research Hospital
Original Assignee
National University of Singapore
St Jude Childrens Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University of Singapore, St Jude Childrens Research Hospital filed Critical National University of Singapore
Publication of CA2926267A1 publication Critical patent/CA2926267A1/en
Application granted granted Critical
Publication of CA2926267C publication Critical patent/CA2926267C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA2926267A 2013-10-17 2014-10-17 Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors Active CA2926267C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361892218P 2013-10-17 2013-10-17
US61/892,218 2013-10-17
US201462026243P 2014-07-18 2014-07-18
US62/026,243 2014-07-18
PCT/US2014/060999 WO2015058018A1 (en) 2013-10-17 2014-10-17 Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors

Publications (2)

Publication Number Publication Date
CA2926267A1 CA2926267A1 (en) 2015-04-23
CA2926267C true CA2926267C (en) 2023-08-01

Family

ID=52828713

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2926267A Active CA2926267C (en) 2013-10-17 2014-10-17 Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors

Country Status (11)

Country Link
EP (1) EP3057986B1 (enExample)
JP (1) JP6417413B2 (enExample)
KR (1) KR102308597B1 (enExample)
CN (1) CN105683214B (enExample)
AU (1) AU2014337195B2 (enExample)
BR (1) BR112016007695A2 (enExample)
CA (1) CA2926267C (enExample)
IL (1) IL245088A0 (enExample)
SG (1) SG11201602979RA (enExample)
WO (1) WO2015058018A1 (enExample)
ZA (1) ZA201602798B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
CA2972714A1 (en) * 2014-09-09 2016-03-17 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
EP3461337A1 (en) 2015-05-06 2019-04-03 Snipr Technologies Limited Altering microbial populations & modifying microbiota
US11517590B2 (en) * 2015-10-08 2022-12-06 National University Corporation Tokai National Higher Education And Research System Method for preparing genetically-modified T cells which express chimeric antigen receptor
BR112018007538A2 (pt) * 2015-10-15 2018-10-23 Celularity Inc células exterminadoras naturais e células ilc3 e usos das mesmas
GB201602974D0 (en) * 2016-02-19 2016-04-06 Clube Jasper R Engineered cells & methods (1)
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
EP3487877A4 (en) * 2016-07-19 2020-01-01 Unum Therapeutics Inc. USE OF THE ANTIBODY COUPLED T CELL RECEPTOR (ACTR) WITH MULTIPLE CANCER ANTIBODIES IN THE TREATMENT OF CANCER
EP3315511A1 (en) 2016-10-29 2018-05-02 Miltenyi Biotec GmbH Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens
AU2017363278B2 (en) 2016-11-22 2022-10-27 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CA3056439A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
SG11201908337VA (en) 2017-03-27 2019-10-30 Nat Univ Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
WO2019056174A1 (zh) * 2017-09-19 2019-03-28 中山大学 一种过表达cxcr5的间质干细胞及其制备方法和用途
NZ766453A (en) 2018-02-01 2022-02-25 Nkmax Co Ltd Method of producing natural killer cells and composition for treating cancer
SG11202007156QA (en) 2018-02-09 2020-08-28 Nat Univ Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2019222642A1 (en) * 2018-05-18 2019-11-21 Senti Biosciences, Inc. Engineered immune cells and methods of use
CN112512573A (zh) * 2018-05-23 2021-03-16 百提威生技股份有限公司 双特异性t细胞衔接蛋白及其用途
EP3817763B1 (en) 2018-07-03 2025-09-03 SOTIO Biotech Inc. Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
BR112021001694A2 (pt) 2018-08-14 2021-05-04 Sotio, LLC polipeptídeos do receptor de antígeno quimérico em combinação com moléculas de metabolismo trans que modulam o ciclo de krebs e seus usos terapêuticos
KR102839381B1 (ko) 2018-08-29 2025-07-28 내셔널 유니버시티 오브 싱가포르 유전적으로 변형된 면역 세포의 생존 및 확장을 특이적으로 자극하는 방법
EP3620464A1 (en) 2018-09-10 2020-03-11 Miltenyi Biotec GmbH Car cell having crosslinked disulfide bridge on antigen recognizing moiety
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2020201527A1 (en) 2019-04-04 2020-10-08 Umc Utrecht Holding B.V. Modified immune receptor constructs
US20220315894A1 (en) 2019-09-11 2022-10-06 Miltenyi Biotec B.V. & Co. KG Method for Transduction of T Cells in the Presence of Malignant Cells
EP3875478A1 (en) 2020-03-05 2021-09-08 Canvax Biotech, S.L. Novel non-immunogenic chimeric antigen receptors and uses thereof
EP3878464A1 (en) 2020-03-09 2021-09-15 Miltenyi Biotec B.V. & Co. KG Use of a car cell having crosslinked disulfide bridge on antigen recognizing moiety for targeting cancer cells
CN113583139A (zh) * 2020-07-06 2021-11-02 上海鑫湾生物科技有限公司 一种嵌合受体及其应用
IL311712A (en) 2021-09-27 2024-05-01 Sotio Biotech Inc Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
EP4572787A1 (en) 2022-08-19 2025-06-25 SOTIO Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
JPH09501055A (ja) 1993-07-30 1997-02-04 ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー 初代リンパ球への効率的遺伝子転移
ATE483472T1 (de) * 2002-05-30 2010-10-15 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20100104564A1 (en) * 2005-03-29 2010-04-29 Genevieve Hansen Altered Antibody Fc Regions and Uses Thereof
US20080003225A1 (en) * 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
CN101855244A (zh) * 2007-08-01 2010-10-06 葛兰素集团有限公司 新型抗体
US8067339B2 (en) * 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
DE102009013748B4 (de) * 2009-03-17 2012-01-26 Paul-Ehrlich-Institut Bestimmung von Interaktionen konstanter Antikörperteile mit Fc-gamma Rezeptoren
AU2010301042B2 (en) * 2009-10-01 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2012021648A1 (en) * 2010-08-10 2012-02-16 Amgen Inc. Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2972714A1 (en) * 2014-09-09 2016-03-17 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy

Also Published As

Publication number Publication date
KR20160062762A (ko) 2016-06-02
ZA201602798B (en) 2018-12-19
AU2014337195B2 (en) 2018-11-08
JP2016534717A (ja) 2016-11-10
JP6417413B2 (ja) 2018-11-07
KR102308597B1 (ko) 2021-10-01
EP3057986B1 (en) 2017-12-27
CA2926267A1 (en) 2015-04-23
EP3057986A4 (en) 2017-03-15
EP3057986A1 (en) 2016-08-24
CN105683214A (zh) 2016-06-15
WO2015058018A1 (en) 2015-04-23
SG11201602979RA (en) 2016-05-30
IL245088A0 (en) 2016-06-30
CN105683214B (zh) 2021-03-09
BR112016007695A2 (pt) 2017-09-12
AU2014337195A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
CA2926267C (en) Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
AU2015315199B2 (en) Chimeric receptors and uses thereof in immune therapy
US10144770B2 (en) Chimeric receptors and uses thereof in immune therapy
AU2019299439B2 (en) Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
RU2732925C2 (ru) МАт-НАПРАВЛЯЕМЫЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРНЫЕ СИСТЕМЫ ДЛЯ СОРТИРОВКИ/ИСТОЩЕНИЯ СКОНСТРУИРОВАННЫХ ИММУННЫХ КЛЕТОК
AU2019206573B2 (en) Immune cells expressing a chimeric antigen receptor
CA3111706A1 (en) Chimeric receptor polypeptides in combination with trans metabolism molecules modulating intracellular lactate concentrations and therapeutic uses thereof
CA2986604A1 (en) Masking chimeric antigen receptor t cells for tumor-specific activation
US20200181226A1 (en) Antibody-coupled t cell receptor constructs and therapeutic uses thereof
US20210261646A1 (en) Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
US20190284298A1 (en) Use of antibody-coupled t cell receptor (actr) with multiple anti-cancer antibodies in cancer treatment
TW202432833A (zh) 新穎ｃｄ１９結合體、包含彼之ｃａｒ—ｔ構築體及其使用方法
WO2018027135A1 (en) Treatment of lymphoma using antibody-coupled t cell receptor
HK1228416A1 (en) Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
HK1228416B (en) Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
CN120548323A (zh) 利用ctla-4变体及嵌合抗原受体的双基因转导免疫细胞及其用途
Achkova Development of Immunotherapy for Classical Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma Using Colony-stimulating Factor-1 Receptor Re-targeted T-lymphocytes

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191009

EEER Examination request

Effective date: 20191009

EEER Examination request

Effective date: 20191009

EEER Examination request

Effective date: 20191009

EEER Examination request

Effective date: 20191009

EEER Examination request

Effective date: 20191009